Back to Story
FILE - A TB (tuberculosis) patient after being administered medication at a clinic in Durban, South Africa on Oct. 17, 2005. Medical advocacy groups have welcomed Johnson & Johnson's decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices. The move comes after South African authorities opened an investigation into the conglomerate. (AP Photo/Themba Hadebe/File)

FILE - A TB (tuberculosis) patient after being administered medication at a clinic in Durban, South Africa on Oct. 17, 2005. Medical advocacy groups have welcomed Johnson & Johnson's decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices. The move comes after South African authorities opened an investigation into the conglomerate. (AP Photo/Themba Hadebe/File)

FILE - The Johnson & Johnson headquarters in New Brunswick, New Jersey, on February 8, 2024. South African authorities have dropped an investigation into Johnson & Johnson for alleged anti-competitive practices after the company agreed not to enforce its patent on a critical TB medication, a move that should allow generic producers to make the drug at much lower prices. (AP Photo/Ted Shaffrey)

FILE - The Johnson & Johnson headquarters in New Brunswick, New Jersey, on February 8, 2024. South African authorities have dropped an investigation into Johnson & Johnson for alleged anti-competitive practices after the company agreed not to enforce its patent on a critical TB medication, a move that should allow generic producers to make the drug at much lower prices. (AP Photo/Ted Shaffrey)

FILE — Nivard Langa, awaits his turn to take tuberculosis (TB) medication at a clinic in Durban, South Africa, on Oct. 17, 2005. Medical advocacy groups have welcomed Johnson & Johnson's decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices. The move comes after South African authorities opened an investigation into the conglomerate. (AP Photo/Themba Hadebe/File)

FILE — Nivard Langa, awaits his turn to take tuberculosis (TB) medication at a clinic in Durban, South Africa, on Oct. 17, 2005. Medical advocacy groups have welcomed Johnson & Johnson's decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices. The move comes after South African authorities opened an investigation into the conglomerate. (AP Photo/Themba Hadebe/File)